Publication:
Mortality according to treatment in metastatic collecting duct renal cell carcinoma

Placeholder

Departments

School / College / Institute

Organizational Unit
Organizational Unit
SCHOOL OF MEDICINE
Upper Org Unit

Program

KU-Authors

KU Authors

Co-Authors

Panunzio, Andrea
Sorce, Gabriele
Tappero, Stefano
Hohenhorst, Lukas
Garcia, Cristina Cano
Piccinelli, Mattia
Tian, Zhe
Tafuri, Alessandro
De Cobelli, Ottavio
Chun, Felix K. H.

Publication Date

Language

Embargo Status

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Large-scale, contemporary, controlled analysis of mortality in metastatic collecting duct renal carcinoma are scarce. Moreover, the optimal management of these patients is unknown. Within the SEER, 155 metastatic collecting duct renal carcinoma patients were identified. Despite the aggressive behavior and dismal survival prognosis, combination of cytoreductive nephrectomy and systemic therapy provide the lowest mortality rates. Introduction: Controlled contemporary analyses of mortality in metastatic collecting duct renal cell carcinoma (mcdRCC) are unavailable. We addressed this knowledge gap and tested rates of treatment and associated mortal-ity in patients with mcdRCC. Patients and Methods: Within Surveillance, Epidemiology, and End Results database (2004-2018), we identified 155 mcdRCC patients. Kaplan-Meier plots and Cox proportional hazards regression models tested the effect of treatment (cytoreductive nephrectomy [CN] alone vs. systemic therapy [ST] alone vs. combination of both CN + ST) on overall mortality (OM). Results: In the overall cohort (n = 155), 57 patients (37%) were treated with combination of both CN + ST, 46 (30%) underwent CN alone, 28 (18%) received ST alone, and 24 (15%) had none/unknown treatment. According to age categories (<= 59 vs. 60-69 vs. > 70 years), rates of combination of both CN + ST were 45% vs. 45% vs. 14%, respectively. CN alone was the most frequent type of treatment in patients aged > 70 (50%). Median overall survival was 4.0 months for CN alone vs. 5.5 months for ST alone vs. 9.0 months for combination of both CN + ST. In multivariable Cox regression models, where CN alone was the referent, the use of ST alone and combination of both CN + ST were respectively associated with a HR of 0.74 ( P = .3) and 0.43 ( P < .001), after adjustment for all covariates. Conclusions: In mcdRCC patients, concomitant use of CN and ST results in lowest mortality, followed by ST alone, and CN alone. In consequence combination of both CN + ST should be recommended whenever applicable.

Source

Publisher

CIG Media Group, Lp

Subject

Oncology, Urology, Nephrology

Citation

Has Part

Source

Clinical Genitourinary Cancer

Book Series Title

Edition

DOI

10.1016/j.clgc.2022.08.010

item.page.datauri

Link

Rights

Copyrights Note

Endorsement

Review

Supplemented By

Referenced By

0

Views

0

Downloads

View PlumX Details